Table 3. Factors associated with overall survival in univariate and multivariate analyses.

	Univariate analysis		Multivariate analysis
Variable	Hazard ratio (95% CI)	P-value	Hazard ratio (95% CI)	P-value
Age >65	0.74 (0.48–1.13)	0.157	0.55 (0.34–0.90)	0.018
Female	1.59 (1.06–2.37)	0.025	1.35 (0.85–2.12)	0.201
PS (ECOG)⩾2	6.14 (3.15–12.0)	<0.001	7.66 (3.68–16.0)	<0.001
BRAF mutant	3.78 (1.89–7.54)	<0.001	4.23 (1.76–10.2)	0.001
KRAS 12 mutant	1.03 (0.62–1.74)	0.897	1.57 (0.88–2.81)	0.128
KRAS 13 mutant	1.67 (0.93–3.02)	0.086	1.51 (0.76–2.98)	0.239
Pathology, por/sig/muc	1.74 (0.96–3.14)	0.066	2.38 (1.16–4.90)	0.018
Number of metastasis ⩾2	0.93 (0.63–1.40)	0.738	1.12 (0.61–2.05)	0.714
Liver metastasis	1.36 (0.88–2.11)	0.162	1.72 (1.02–2.90)	0.042
Lung metastasis	0.66 (0.42–1.02)	0.061	0.59 (0.32–1.11)	0.100
Peritoneal metastasis	1.21 (0.76–1.93)	0.417	1.56 (0.85–2.88)	0.154
WBC ⩾10000	1.27 (0.51–3.15)	0.605	—	—
ALP ⩾300	1.21 (0.78–1.88)	0.395	—	—
Anti-EGFR treatment	0.80 (0.53–1.20)	0.277	—	—

Abbreviations: ALP=alkaline phosphatase; PS=performance status; ECOG=Eastern Cooperative Oncology Group; EGFR=epidermal growth factor receptor; por=poorly differentiated adenocarcinoma; muc=mucinous carcinoma; sig=signet-ring cell carcinoma; CI=confidence interval; WBC=white blood cells.